MSH2 gene
Evidence from:
primary |
all sources
Related entities (2)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| MSH2 | associated_with | cancer | — | 1 |
| MSH2 | risk_factor_for | cancer | — | 1 |
Mentioned in (30)
Papers in which this entity is mentioned.
- Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types. (2026)
- Synchronized long-read genome, methylome, epigenome and transcriptome profiling resolve a Mendelian condition. (2025)
- Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types from 10,983 cancer patients (2023)
- Heritable defects in telomere and mitotic function selectively predispose to sarcomas. (2023)
- Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. (2022)
- Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. (2021)
- Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. (2021)
- Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. (2021)
- DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. (2020)
- Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. (2020)
- The GenomeAsia 100K Project enables genetic discoveries across Asia. (2019)
- Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients. (2019)
- Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. (2019)
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. (2018)
- Comprehensive Characterization of Cancer Driver Genes and Mutations. (2018)
- Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. (2018)
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. (2017)
- Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines. (2017)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. (2017)
- Comprehensive Analysis of Hypermutation in Human Cancer. (2017)
- New insights into the generation and role of de novo mutations in health and disease. (2016)
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. (2016)
- Integrative clinical genomics of advanced prostate cancer. (2015)
- Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. (2014)
- Exon identity crisis: disease-causing mutations that disrupt the splicing code. (2014)
- Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. (2013)
- High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. (2012)
- Linking functional decline of telomeres, mitochondria and stem cells during ageing. (2010)
- Common and rare variants in multifactorial susceptibility to common diseases. (2008)
- MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. (2008)
Merged raw entities (1)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| msh2 | gene | 30 | 55 |